1415901-85-7

Basic information

• Product Name: 3-({2-[(4-{amino-[(E)-isopropyloxycarbonylimino]methyl}-phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid ethyl ester
• CAS NO: 1415901-85-7
• Molecular Weight: 585.663
• Mol File: 1415901-85-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-({2-[(4-{amino-[(E)-isopropyloxycarbonylimino]methyl}-phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-({2-[(4-{amino-[(E)-isopropyloxycarbonylimino]methyl}-phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid ethyl ester(1415901-85-7)
• EPA Substance Registry System: 3-({2-[(4-{amino-[(E)-isopropyloxycarbonylimino]methyl}-phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid ethyl ester(1415901-85-7)

Safety Data

• Hazardous Substances Data: 1415901-85-7(Hazardous Substances Data)

Upstream product

• 108-23-6 isopropyl chloroformate 
• 1746-77-6 isopropyl carbamate 

Downstream Products

• 1415901-89-1 3-({2-[(4-{amino-[(E)-isopropyloxycarbonylimino]methyl}-phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid 
• 1415901-80-2 C₃₇H₄₁N₉O₅ 
• 1419178-63-4 3-({2-[(4-{amino-[(E)-isopropyloxycarbonylimino]methyl}phenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid {2-methoxy-4-[(E)-2-methoxycarbonylvinyl]phenyl} ester 

Relevant articles and documents

Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate

A novel series of prodrugs containing dabigatran and methyl (E)-3-(4-hydroxy-2-methoxyphenyl)propenoate (methyl ferulate) were synthesized. All of them reveal the effect of thrombin-induced anti-platelet aggregation in vitro. In addition, in vivo experiment shows that one of the target compounds, X-2 (ED50 = 3.7 ± 1.0 μmol/kg) possesses a more potent activity for inhibiting venous thrombosis than that of dabigatran etexilate (ED50 = 7.8 ± 1.5 μmol/kg).

Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity

A novel series of prodrugs consisting of dabigatran and 2-hydroxymethyl-3,5,6-trimethylpyrazine (HTMP) were synthesized. The pharmacological results show that all of them possess the effect of anti-platelet aggregation induced by thrombin in vitro. Moreover, one of those compounds, Y-2 (ED50 = 2.1 ± 1.3 mg/kg) shows more potent activity for inhibiting thrombosis in vivo than that of dabigatran etexilate (ED50 = 4.4 ± 2.2 mg/kg).